Overview

Observation of the Use of QUTENZA™ in Standard Clinical Practice

Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
This non-interventional study will evaluate the efficacy, tolerability, health related quality of life and use of health resources associated with QUTENZA treatment when QUTENZA is used in standard clinical practice. The patient's primary diagnosis of peripheral neuropathic pain (PNP) will be classified into subtypes: post-herpetic neuralgia (PHN); HIV-associated neuropathy (HIV-AN); neuropathic back pain; cancer-related neuropathic pain; post-operative & post-traumatic neuropathic pain; and 'other' neuropathies.
Details
Lead Sponsor:
Astellas Pharma Europe Ltd.
Treatments:
Capsaicin